Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research R. JagsiG. MasonSusan G. Komen-IBCRF IBC Collaborative in partnership with the Milburn Foundation Review Open access 01 January 2022 Pages: 235 - 243
Correction to: Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research R. JagsiG. MasonSusan G. Komen-IBCRF IBC Collaborative in partnership with the Milburn Foundation Correction 08 February 2022 Pages: 245 - 247
Hypofractionated proton therapy in breast cancer: where are we? A critical review of the literature Daniela AlterioEliana La RoccaBarbara Alicja Jereczek-Fossa Review 13 January 2022 Pages: 249 - 263
IMPARTER, Phase 1 of an intervention to improve patients’ understanding of gene expression profiling tests in breast cancer L. J. FallowfieldD. FarewellV. Jenkins Preclinical study Open access 04 January 2022 Pages: 265 - 271
Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer Richard A. AndersonTom W. KelseyFlorian Clatot Preclinical study Open access 08 January 2022 Pages: 273 - 282
Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability Aglaya G. IyevlevaSvetlana N. AleksakhinaEvgeny N. Imyanitov Preclinical study 12 January 2022 Pages: 283 - 291
Preventing taxane-related peripheral neuropathy, pain and nail toxicity: a prospective self-controlled trial comparing hilotherapy with frozen gloves in early breast cancer Annemarie CoolbrandtK. VancoilleH. Wildiers Clinical trial 04 January 2022 Pages: 293 - 301
Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer Yee-Ming M. CheungGrace E. CromwellMarie E. McDonnell Clinical trial 09 January 2022 Pages: 303 - 311
Impact of body mass index on the efficacy of aromatase inhibitors in patients with metastatic breast cancer Rima PatelZhiqiang LiAmy Tiersten Clinical trial 10 January 2022 Pages: 313 - 319
The progesterone-receptor modulator, ulipristal acetate, drastically lowers breast cell proliferation Carolyn L. WesthoffHua GuoRichard Ha Clinical trial 11 January 2022 Pages: 321 - 329
The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry Marissa MeegdesKhava I. E. IbragimovaVivianne C. G. Tjan-Heijnen Clinical trial Open access 13 January 2022 Pages: 331 - 342
Ki-67 and breast cancer prognosis: does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen? Soon Bo ChoiJung Min ParkSeho Park Clinical trial Open access 13 January 2022 Pages: 343 - 352
Tumor-promoting mechanisms of macrophage-derived extracellular vesicles-enclosed microRNA-660 in breast cancer progression Changchun LiRuiqing LiGuoqing Jiang Clinical trial 27 January 2022 Pages: 353 - 368
Contribution of cost to treatment nonadherence in the US breast cancer survivors: a population-based analysis Caiwei ZhengAnees B. Chagpar Epidemiology 06 January 2022 Pages: 369 - 373
Feasibility of personalized screening and prevention recommendations in the general population through breast cancer risk assessment: results from a dedicated risk clinic Mahasti SaghatchianMarc AbehseraDominique Stoppa-Lyonnet Epidemiology 07 January 2022 Pages: 375 - 383
Barriers and facilitators to taking CDK4/6 inhibitors among patients with metastatic breast cancer: a qualitative study Claire C. ConleyMcKenzie McIntyreSuzanne C. O’Neill Epidemiology 07 January 2022 Pages: 385 - 399
Insulin resistance and the development of breast cancer in premenopausal women: the Kangbuk Samsung Health Study Jeesun LeeYoosoo ChangSeungho Ryu Epidemiology 08 January 2022 Pages: 401 - 409
Lack of racial differences in clinical outcomes of breast cancer patients receiving neoadjuvant chemotherapy: a single academic center study Maithreyi SarmaStuthi PerimbetiShipra Gandhi Epidemiology 09 January 2022 Pages: 411 - 421
The relationship between sleep and weight change among women diagnosed with breast cancer participating in the Women’s Health Initiative Sidney M. DonzellaKimberly E. LindTracy E. Crane Epidemiology 10 January 2022 Pages: 423 - 433
Breast cancer treatment patterns by age and time since last pregnancy in the Carolina Breast Cancer Study Phase III Sanah N. VohraKatherine E. Reeder-HayesMelissa A. Troester Epidemiology 10 January 2022 Pages: 435 - 445
Racial differences in breast cancer outcomes by hepatocyte growth factor pathway expression Gieira S. JonesKatherine A. HoadleyMelissa A. Troester Epidemiology 16 January 2022 Pages: 447 - 455
Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients Maria Alice FranzoiMatteo LambertiniEvandro de Azambuja Brief Communication 25 January 2022 Pages: 457 - 462
Comment on: sarcopenia and serum biomarkers of oxidative stress after a 6-month physical activity intervention in women with metastatic breast cancer—results from the ABLE feasibility trial Irem Kirac UtkuUmut Safer Letter to the Editor 07 January 2022 Pages: 463 - 463
